胃癌p53等蛋白表达与患者生存期及预后的关系

目的：探讨p53、血管内皮生长因子(VEGF)和c-erbB-2表达与胃癌生物学行为的关系。方法：采用免疫组化方法研究87例胃癌中p53，VEGF和c-ebB-2蛋白的表达。结果：正常胃黏膜p53，c-erbB-2均阴性，胃癌组织中p53，VEGF，c-erhB-2阳性率分别为47．1％，49．4％，40．2％。p53与胃癌淋巴结转移相关，P&;lt;0．05。VEGF与胃癌生长方式、浸润深度及预后等关系密切，P&;lt;0．05。c-erhB-2与胃癌的分化程度、淋巴结转移及预后关系密切，P&;lt;0．05。p53蛋白的表达与患者生存期无明显关系，随患者生存期的延长，胃癌组织内VEGF，c-erbB-2有下降趋势。结论：p53蛋白是预测胃癌生物学行为的有用指标，VEGF，c-erhB-2一起可用于判断胃癌预后，监测病情。     

p53蛋白、ki-67抗原和表皮生长因子受体在胃癌组织的表达及意义

目的探讨胃癌组织中p53蛋白、ki-67抗原和表皮生长因子受体(EGFR)表达与TNM分期的关系。方法回顾性分析胃癌手术标本66例,采用免疫组织化学MaxVisionTM2/HRP法检测66例胃癌组织中p53、ki-67和EGFR的表达,分析其临床病理特征及与预后的关系。结果各分子标记物在胃癌组织中的阳性表达率为:p53蛋白53.03%(35/66),ki-67抗原62.12%(41/66),EGFR 42.42%(28/66)。P53蛋白表达与胃癌病灶直径、淋巴结转移密切相关(P<0.05),ki-67抗原阳性表达与胃癌分化密切相关(P<0.05),EGFR阳性表达与胃癌浸润深度、淋巴结转移密切相关(P<0.05)。p53、ki-67、EGFR三者联合检测与胃癌TNM分期密切相关(P<0.05)。结论 p53、ki-67、EGFR三者联合检测优于单独检测,与胃癌TNM分期相关。     

livin和P53蛋白在胃癌及癌旁组织中的表达及临床意义

目的探讨livin和P53在胃癌及癌旁组织中的表达及临床意义。方法应用免疫组织化学方法检测40份胃癌组织及癌旁正常组织中livin和P53蛋白表达情况。结果胃癌组织中livin和P53蛋白阳性表达率分别为47.5%和52.5%,癌旁正常组织中阳性表达率分别为5.0%和12.5%,差异有统计学意义(P<0.05);伴淋巴结转移的胃癌组织中livin表达阳性率高于无淋巴结转移的胃癌组织(P<0.05),Ⅲ+Ⅳ期胃癌组织中livin及P53蛋白阳性表达率高于Ⅰ+Ⅱ期(P<0.05);livin与P53蛋白表达无相关性(P>0.05)。结论 livin与P53蛋白异常表达与胃癌的恶性生物学行为有关,其表达对临床上判断胃癌的预后有重要意义。     

乳腺癌组织蛋白酶D、c-erbB-2、P53、P16、nm23蛋白表达与淋巴结转移的关系

目的:探讨乳腺癌组织蛋白酶D(Cath-D)、c-erbB-2、P53、P16、nm23蛋白的表达与淋巴结转移的关系。方法:应用免疫组织化学S-P法,检测100例乳腺癌Cath-D、c-erbB-2、P53、P16、nm23蛋白的表达情况。结果:Cath-D、c-erbB-2、P53、P16、nm23蛋白阳性表达率分别为61%、55%、60%、47%、58%。有腋窝淋巴结转移患者的Cath-D、c-erbB-2、P53阳性表达率明显高于无转移者(P<0.01),有腋窝淋巴结转移患者的P16、nm23蛋白阳性表达率明显低于无转移者(P<0.01)。结论:Cath-D、c-erbB-2、P53的高表达与P16、nm23蛋白的低表达可能促进乳腺癌的淋巴结转移,联合检测以上生物学指标有助于提高对乳腺癌预后评价和治疗的正确性。     

癌基因c-erbB-2、组织蛋白酶D在胃癌中的表达及其意义

目的 探讨癌基因c-erbB-2、组织蛋白酶D（Cath-D)在胃癌中的表达及其与胃癌发展的关系。方法 应用免疫组织化学方法检测102例胃癌组织的c-erbB-2、Cath-d蛋白表达，分析其与胃癌生物学行为之间的关系。结果 c-erbB-2阳性率38.2%，Cath-D阳性率81.4%。c-erbB-2阳性者Cath-D的阳性率明显高于c-erbB-2阴性者，c-erbB-2和Cath-D表达与胃癌浸润深度、淋巴结转移密切相关，而与组织学分型无关。Cath-D表达还与肿瘤的生长方式及脉管内癌栓有关；c-erbB-2和Cath-D表达阳性的胃癌患者5年生存率较表达阴性者低。结论 c-erbB-2和Cath-D对胃癌的生长、浸润和转移有促进作用，c-erbB-2和Cath-d可作为反映胃癌生物学行为的指标之一。     

乳腺癌组织中表皮生长因子受体的表达与c-erbB-2、p53的相关性及其临床意义

目的探讨乳腺癌组织中表皮生长因子受体(EGFR)的表达,并探讨其与乳腺癌临床病理特征以及与c-erbB-2和p53的相关性。方法用免疫组织化学法检测84例乳腺癌标本中EGFR、c-erbB-2及p53的表达情况,分析不同临床病理特征与其表达的关系。结果乳腺癌中EGFR、c-erbB-2和p53的阳性表达率分别是64.3%、54.8%和44.0%。EGFR的表达与病理类型、组织学分级、TNM分期有关(P<0.05,P<0.01,P<0.01);c-erbB-2(+)组EGFR的阳性表达率(73.9%,34/46)明显高于c-erbB-2(-)组(52.6%,20/38)(P<0.05);p53(+)组EGFR的阳性表达率(81.1%,30/37)明显高于p53(-)组(51.1%,24/47)(P<0.01)。结论联合检测乳腺癌组织中EGFR、c-erbB-2及p53的表达对于判断乳腺癌预后和指导治疗具有临床参考价值。     

乳腺癌组织中雌孕激素受体、c-erbB-2、p53、bcl-2及pS2的表达及意义

目的探讨乳腺癌组织中雌激素受体（ER）、孕激素受体（PR）、c-erbB-2、p53、bcl-2及pS2的表达及其临床意义。方法用免疫组织化学法检测75例乳腺癌标本中ER、PR、c-erbB-2、p53、bcl-2及pS2蛋白的表达情况,分析不同临床病理特征与其表达的关系。结果乳腺癌中ER、PR、C-erbB-2、p53、bcl-2和pS2的阳性表达率分别为74.7%、78.7%、49.3%、65.3%、82.7%和54.7%。PR的表达与患者年龄相关;p53的表达与组织学分级、病理类型、淋巴结转移、肿瘤位置和临床分期有关;bcl-2的表达与年龄、月经和肿瘤位置有关;pS2与绝经状况有关;bcl-2的表达与ER有关;ER（＋）、PR（＋）组中pS2阳性率明显高于ER（-）、PR（-）组（P〈0.05）。结论联合检测乳腺癌组织中ER、PR、c-erbB-2、p53、pS2及bcl-2蛋白的表达对于判断乳腺癌预后和指导治疗具有临床参考价值。     

胃癌中p53基因与血管内皮生长因子表达的关系

[目的]探讨P53蛋白和血管内皮生长因子(VEGF)在胃癌中的表达及其与临床病理特征的关系.[方法]采用免疫组化S-P法检测45例手术切除胃癌组织中P53蛋白、VEGF的表达和微血管密度(MVD),分析其与肿瘤浸润、淋巴结转移和远处转移的关系.[结果]在45例胃癌中P53蛋白的阳性表达率为51.11%(23/45),VEGF的阳性表达率为66.67%(30/45),MVD计数为43.6士12.5(x±s);在VEGF高表达的区域,P53蛋白的表达亦增强,二者密切相关(P＜0.05);P53蛋白、VEGF表达阳性的病例,其肿瘤组织中MVD明显高于阴性者(P＜0.05或P＜0.01);P53蛋白、VEGF的表达与肿瘤的淋巴结转移、远处转移密切相关(P＜0.05).[结论]胃癌组织中VEGF的表达与P53蛋白的阳性率呈正相关,二者在肿瘤组织的血管生成和侵袭转移中起重要作用.     

胃癌p53、c-erbB-2、p21、nm23基因表达的分布特点及其临床意义

目的为探讨手术切除胃癌组织p53、c-erbB-2、p21、nm23联合基因产物表达检测对胃癌诊断治疗及预后判断的价值。方法应用免疫组化技术检测了手术切除胃癌组织p53c、-erbB-2、p21、nm23基因产物表达。结果p53蛋白表达阳性率为36.4%~46.7%,c-erbB-2为33.3%~56.8%,p21为35.1%~56.7%,nm23为30.0%~70.5%。在非胃癌组织中(胃,十二指肠溃疡,胃息肉,重度不典型增生)未见c-erbB-2、p21、nm23基因表达。p53c、-erbB-2、p21的表达与胃癌的分化程度,肿瘤浸润程度,肿瘤转移程度及临床分期呈正相关。nm23的表达与胃癌的分化程度,肿瘤浸润程度,肿瘤转移程度及临床分期呈负相关。p53c、-erbB-2、p21n、m23四种肿瘤蛋白在胃镜活检标本和手术切除标本中表达无显著性差异,胃镜活检标本和手术切除标本检测阳性符合率分别为90.2%、91.0%、93.7%和89.3%。结论对胃癌组织p53、c-erbB-2、p21、nm23基因表达检测在胃部良恶性肿瘤鉴别,非手术临床分期的判断及指导临床治疗等方面具有一定价值。多基因表达检测对胃癌预后判断明显优于单基因表达检测。     

CD44V6和MMP-9及P53的表达与胃癌患者淋巴结转移的关系--附60例检测报告

目的:探讨CD44第6变异株(CD44V6)、金属基质蛋白酶-9(matrix metalloproteinase-9,MMP-9)、P53蛋白表达与胃癌患者淋巴结转移的关系.方法:采用分子原位杂交和免疫组织化学方法对60例胃癌患者癌组织中的CD44V6信使核糖核酸(messenger ribonucleic acid,mRNA)、MMP-9mRNA和P53蛋白的表达进行检测.结果:胃癌组织中CD44V6mRNA、MMP-9 mRNA、P53蛋白表达阳性率分别为60%、63%、65%,CD44V6mRNA、MMP-9 mRNA、P53蛋白阳性表达者的淋巴结转移率分别为92%、92%、90%,均明显高于阴性者的38%、32%、33%,P＜0.05;同时有2个以上指标表达者的淋巴结转移率为100%,明显高于1个指标表达者(20%)和3个指标均不表达者(23%),差异均有统计学意义(P＜0.05).结论:CD44V6mRNA、MMP-9 mRNA和P53蛋白的异常表达与胃癌淋巴结转移过程密切相关,对分析胃癌的生物学行为和判断预后有重要意义.     

Interaction of peptidoglycans with anti-IgGs and with complement.

This report describes the interaction of peptidoglycan (Streptococcus group A, Staphylococcus epidermidis and Micrococcus lysodeikticus) with 2 serum mediator systems, namely with the anti-IgG system and with complement. The observation that the majority of rabbits hyperimmunized with A-variant streptococcal vaccine produced anti-group carbohydrate antisera containing anti-IgGs and antibodies directed to peptidoglycan suggested that the production of these 2 latter antibodies was related. This view was supported by the finding of a monoclonal 7S anti-IgG with antibody specificity for the pentapeptide of peptidoglycan as evidenced by inhibition of the coprecipitation of 7S anti-IgG with antigen-antibody complexes by the pentapeptide. Inhibition of the anti-idiotype reaction by the pentapeptide provided further evidence for the antibody specificity of 7S anti-IgG for peptidoglycan. When added to normal human sera all peptidoglycan preparations inhibited the hemolytic activity of the sera. Consumption of C3 in C2 deficient serum and consumption of C2 in normal serum indicated the activation of both known complement pathways. Activation of the classical pathway of complement was more efficient since 50 mug of peptidoglycan consumed approximately 70% of C2 per ml normal serum whereas more than 2 mg of the same preparations was required to inactivate 17-24% of C3 in C2 deficient sera. Each of the different peptidoglycan preparations consumed similar amounts of complement in all 20 sera tested. This finding suggested that activation of the classical complement pathway by peptidoglycan was not mediated by anti-peptidoglycan antibodies present in only 20-40% of normal human sera.     

异病酚静脉全麻下复合氯胺酮或曲马多行纳屈酮快速阿片脱毒的效果比较

Toreleasetheseverewithdrawalsymptomsoftheheroinad-dicts,weinjecttheNaloxineinthegeneralanesthesia.160volun-teersreceivedRODwereperformedunderthecombinedanesthesiawithpropofol,midazolamandketamine.1Subjectsandmethods1.1Subjects160volunteerswhoaccordingwiththediagnosticstandardoftheICD-10abouttheopiate-addiction,male:145,fe-male15.Age:(30±6),theeldestwas45yearsold.Themeanbodyweightwasabout(58±8)kg.Educationalbackground:pri-maryschool118cases,juniorhighschool:24casesandseniorhighschool/seco…     

The comparison of effects of rapid opiate detoxification with ketamine complex and with tramadol and naltrexone under general anesthesia with propofol

Objective To release the heroin addicts‘ sufferings,we made rapid opiate detoxification by injecting naloxine under the general anesthesia.Method 160 volunteers were divided at randon into two groups:Group A were performed under the combined anesthesia with propofol,midazolam and kelamine.Group B were performed under the combined anesthesia with propofol with midazolam and tramadol.The vital signs were recorded and the withdrawal syndrome of the volunteers were assessed during the whole process.Result All of the withdrawal symptoms scores 24 hours after ROD in group B were lower than its pre-treatment;The symptoms of the thirs,tsleeping disturbance,nausea and vomiting,skeletal muscular pains and anorexia scores in group A were also lower than its pre-treatment;and no too much differeence belween group A and group B.But tearing,anxiety and diarrhea scores in group A were almost the same as the pre-treatment and higher than group B.Both groups received of the naloxone treatment smoothly,and remained in the hospital for about 3 days.Conclusion The effect of rapid opiate detoxification of naltrexone with the ketamine or tramadol under anesthesia is obvious.The tramadol is better than others.     

替吉奥联合亚叶酸钙及奥沙利铂治疗晚期结直肠癌病人的观察与护理

[目的]总结替吉奥联合亚叶酸钙及奥沙利铂治疗晚期结直肠癌病人的观察与护理。[方法]对25例无法手术切除的晚期结直肠癌病人采用替吉奥胶囊联合亚叶酸钙、奥沙利铂方案进行治疗,同时加强心理护理、毒副反应的观察与护理等。[结果]治疗过程中出现Ⅰ级和Ⅱ级神经毒性8例,恶心、呕吐、食欲下降12例,骨髓抑制5例,变态反应1例,经处理后均好转;1例病人死亡,其余病人均顺利进行治疗。[结论]加强替吉奥联合亚叶酸钙及奥沙利铂治疗晚期结直肠癌病人的护理,可保证治疗的顺利进行。     

缩腺液治疗扁桃体炎的疗效观察及其护理

扁桃体炎是儿童常见病、多发病,传统药物治疗可暂缓症状,但不能根治;手术治疗痛苦大、出血多、费用高,常合并有并发症。我科运用缩腺液治疗扁桃体炎3 0例收到了良好的效果。现报告如下。1　对象与方法1.1　对象　本科于2 0 0 2年—2 0 0 3年共收治扁桃体炎病人5 0例,年龄为7岁～2 0岁,分两组进行。缩腺液治疗组3 0例,男13例,女17例;其中重度12例,中度9例,轻度9例;对照组2 0例,男9例,女11例;其中重度8例,中度7例,轻度5例。两组病人年龄、性别、病情严重程度基本一致,差异无统计学意义(P >0 .0 5 )。1.2　方法　对照组采用药物治疗,静脉输注…     

艾滋病合并结核病及马尔尼菲青霉病患者的护理

目的 通过分析艾滋病合并结核病及马尔尼菲青霉病患者的临床资料,提高对三病并存的护理认识.方法 分析并总结26例艾滋病合并结核病及马尔尼菲青霉病住院患者的临床特点、治疗及护理方法.结果 本组患者治愈5例,好转13例,死亡8例.存活患者随访6～30个月均未复发.结论 三病并存时临床表现复杂,无特异性,护理难度大,应仔细观察病情,及早诊治,精心护理,对改善预后有重要意义.     

艾滋病合并结核病及马尔尼菲青霉病患者的护理

目的通过分析艾滋病合并结核病及马尔尼菲青霉病患者的临床资料,提高对三病并存的护理认识。方法分析并总结26例艾滋病合并结核病及马尔尼菲青霉病住院患者的临床特点、治疗及护理方法。结果本组患者治愈5例,好转13例,死亡8例。存活患者随访6～30个月均未复发。结论三病并存时临床表现复杂,无特异性,护理难度大,应仔细观察病情,及早诊治,精心护理,对改善预后有重要意义。     

Coping and compensation strategies of patients with disseminated encephalomyelitis and of patients with schizophrenic psychoses]

In ten patients with schizophrenic psychosis and ten patients with multiple sclerosis, the coping and compensation strategies were examined by means of semistructured interviewing. The following categories were considered: 1. avoidance; 2. habituation and/or adaptation to the disease; 3. efforts to compensate the deficits by will-power; 4. efforts to train certain types of behaviour; 5. self-treatment; 6. disease awareness and insight. Examples for these categories are given for both groups of patients. There is a surprising similarity in the statements made by the schizophrenic patients and those with multiple sclerosis. All of the patients with multiple sclerosis had developed coping strategies against psychological symptoms. It is suggested that the neuropsychological deficits in multiple sclerosis resemble the symptoms of reduced energetic potential observed in schizophrenia. In both groups efforts should be made to activate the compensation strategies by adequate training procedures.     

Experience with the treatment of atrial fibrillation with cordarone and digoxin

Paraxysmal and recent cardiac fibrillations have been treated in 42 patients with cordaron combined with digoxin. The arrest of fibrillation was achieved for 5 days in 29 patients (69%) suggesting high efficacy of the combination.